ORM-6151 is a monoclonal antibody drug that targets CD33 and GSPT1, developed by Orum Therapeutics.

Fresenius Kabi made an announcement about the introduction of Tyenne®, its tocilizumab biosimilar which references the RoActemra® (tocilizumab) in the European Union.

This article summarized the latest R&D progress of Nelarabine, the Mechanism of Action for Nelarabine, and the drug target R&D trends for Nelarabine.

In late October, Hengrui and Merck agreed on a €1.4 billion transaction, with a first payment of €160 million. The deal mainly involves Hengrui's self-developed PARP1 inhibitor HRS-1167 and Claudin-18.2 ADC SHR-A1904.

This article summarized the latest R&D progress of Lotilaner, the mechanism of action for Lotilaner, and the drug target R&D trends for Lotilaner.

Recent trial findings of Junshi Biosciences' Toripalimab and Cetuximab combo for treating R/M-HNSCC were shared at the 38th annual SITC meeting in 2023.

This article summarized the latest R&D progress of Mebeverine Hydrochloride, the mechanism of action for Mebeverine Hydrochloride, and the drug target R&D trends for Mebeverine Hydrochloride.

The D2 receptor is a type of dopamine receptor found in the human body. It plays a crucial role in various physiological and neurological processes.

This article summarized the latest R&D progress of Melarsoprol, the Mechanism of Action for Melarsoprol, and the drug target R&D trends for Melarsoprol.

Innovent Biologics reported two clinical research outcomes at the 2023 AAO annual meeting on Nov 6, 2023. These include the Phase 2 clinical data for IBI302, an anti-VEGF-anti-complement dual target drug for nAMD treatment, and Phase 1 clinical data for IBI324, an anti-VEGF-A/Ang-2 bispecific antibody for DME treatment.

This article summarized the latest R&D progress of Menotropins, the Mechanism of Action for Menotropins, and the drug target R&D trends for Menotropins.

In biology, linkers refer to short amino acid sequences found in nature that separate multiple domains in a single protein.